Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06868914 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of High-Density Theta Burst Stimulation (hdTBS)
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Not yet
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT06868914 is a Phase 1 study that has not yet begun recruiting, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 35 participants.
The verdict
NCT06868914, a Phase 1 study, has not yet begun recruiting, sponsored by National Institute on Drug Abuse (NIDA).
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
Background: Transcranial magnetic stimulation (TMS) uses magnetic pulses to affect brain activity. A type of TMS called theta burst stimulation (TBS) is approved to treat people with major depression. Researchers have developed a new form of TBS called high-density TBS (hdTBS). They hope hdTBS will work better than TBS. But first they need to test the new treatment in healthy adults. Objective: To test hdTBS in healthy adults. Also, to compare the aftereffects of hdTBS and TBS. Eligibility: Healthy adults aged 22 to 60 years. Design: Participants will have 4 clinic visits over about 3 to 4 weeks. They must abstain from drugs and alcohol and limit caffeine before visits. At their first visit, participants will be oriented to TBS. They will wear a cap and earplugs. A device with round coils will be placed near their head. When a brief electric current passes through the coil, it generates a magnetic pulse that stimulates the brain. Participants may feel a pulling sensation on the skin under the coil. Their fingers may move involuntarily. At their next 3 visits, participants will receive either TBS or sham TBS. A sham TBS uses a low magnetic field to minimize the effects of the treatment. Participants will have up to 9 electrodes placed on 1 arm. These electrodes will measure the electrical activity in their muscles. Each TBS session will be videotaped. At every visit, participants will answer questions about their health, including substance use. They will perform 2 tasks to test their thinking skills. They will perform a test on a computer to test their reaction time....
Interventions
- DEVICE TMS (MagVenture MagPro 100 with MagOption)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-07-15 |
| Est. Completion | 2028-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06868914
The ClinicalTrials.gov registry entry for NCT06868914 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TMS (MagVenture MagPro 100 with MagOption) is the first listed.
NCT06868914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06868914 about?
NCT06868914 is a clinical study titled "Phase I Trial of High-Density Theta Burst Stimulation (hdTBS)". Background: Transcranial magnetic stimulation (TMS) uses magnetic pulses to affect brain activity. A type of TMS called theta burst stimulation (TBS) is approved to treat people with major depression. Researchers have developed a new form of TBS called high-density TBS (hdTBS). They hope hdTBS will...
What is the current status of trial NCT06868914?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2026-07-15. Estimated completion is 2028-01-13.
What interventions are being tested in trial NCT06868914?
The interventions under investigation include: TMS (MagVenture MagPro 100 with MagOption) (DEVICE).
Who is sponsoring clinical trial NCT06868914?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.